The Combination of a Human Biomimetic Liver Microphysiology System with BIOLOGXsym, a Quantitative Systems Toxicology (QST) Modeling Platform for Macromolecules, Provides Mechanistic Understanding of Tocilizumab- and GGF2-Induced Liver Injury.

However, tocilizumab treatment at 232 μg/mL produced significant increases in high mobility group box 1 protein (HMGB1) release at day 3 of treatment, and tocilizumab treatment (232 and 725 μg/mL) showed an increasing trend in HMGB1 release at day 10 of treatment ( Figure 1 B,C).

also in 63,971 other papers